← FDA DRUG APPROVALS

FDA ANDA · ANDA200265

VORICONAZOLE

Sponsor: SANDOZ INC

APPLICATION
ANDA200265
TYPE
ANDA
ORIGINAL APPROVAL
2011-12-12
LATEST ACTION
2022-12-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

VORICONAZOLEPrescription
VORICONAZOLE 200MG · TABLET · ORAL
VORICONAZOLEPrescription
VORICONAZOLE 50MG · TABLET · ORAL

Approval history

2022-12-14Labeling · Supplement 21 · standardAP
2022-12-14Labeling · Supplement 20 · standardAP
2022-06-13Labeling · Supplement 19 · standardAP
2022-06-13Labeling · Supplement 17 · standardAP
2022-06-13Labeling · Supplement 15 · standardAP
2022-06-13Labeling · Supplement 18 · standardAP
2022-06-13Labeling · Supplement 16 · standardAP
2019-07-08Labeling · Supplement 12 · standardAP
2019-07-08Labeling · Supplement 10 · standardAP
2015-10-30Labeling · Supplement 9 · standardAP
2015-10-30Labeling · Supplement 8 · standardAP
2011-12-12Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →